Cancer Research
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the initiation of a Phase 2 investigator-sponsored study of evorpacept, a next generation CD47 blocker, in combination with…
Read More
Company Creates “Younger T Cells” for Fighting Cancer Using its NR2F6 Technology Excerpt from the Press Release: SAN DIEGO, Aug. 11, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced today the filing with the United States Patent and Trademark Office of a provisional US patent application covering the Company’s novel approach for…
Read More
– The pivotal Precision-T Study is evaluating the safety and efficacy of Orca Bio’s investigational Orca-T compared to standard of care allogeneic hematopoietic stem cell transplant – – Precision-T is expected to enroll approximately 174 patients across more than 20 clinical trial sites – Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Orca Bio, a late-stage…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] announced that Ipsen, SA (“Ipsen”) has issued a press release today reporting its primary analysis of the results of its Phase 3 trial of Onivyde® (irinotecan liposomal injection) as a treatment of second line small cell lung cancer (SCLC).…
Read More
–The NCI-backed “Molecular Targets Platform” will streamline and catalyze drug development by harmonizing data about pediatric cancer targets and pathways— Excerpt from the Press Release: PHILADELPHIA, Aug. 4, 2022 /PRNewswire/ — Children’s Hospital of Philadelphia (CHOP) has helped launch a new computational platform that will harmonize pediatric cancer data, allowing researchers, pharmaceutical companies, and advocacy…
Read More
Certara and Memorial Sloan Kettering Cancer Center to develop biosimulation platform for CAR T-cell therapies Excerpt from the Press Release: PRINCETON, N.J., July 28, 2022 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a 2-year collaboration with Memorial Sloan Kettering Cancer Center (MSK) to develop new biosimulation software. Certara…
Read More
Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that Part A of the Phase 3 CheckMate -914 trial, evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as an adjuvant treatment for patients with localized renal cell carcinoma (RCC) who have undergone full or partial removal of the kidney and who are at moderate or high risk…
Read More
Excerpt from the Press Release: NOVATO, Calif., July 28, 2022 /PRNewswire/ — QT Imaging, Inc., a medical device company focused on the development and clinical adoption of novel products for body imaging, today announced results of a National Cancer Institute study comparing the QTscan with 7-Tesla MRI for prostate cancer screening. In an initial series of 10 patients,…
Read More
— Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma — — First data from phase 1 investigator-sponsored clinical study of TORC 1/2 inhibitor sapanisertib in combination with telaglenastat in patients with non-small cell lung cancer — Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., July 13,…
Read More
Findings from a large, multi-cohort study suggest the genomic test can improve care for lung nodule patients with inconclusive bronchoscopy results Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Jul. 13, 2022– Veracyte, Inc. (Nasdaq: VCYT) announced that new data published today in PLOS ONE show that the company’s Percepta Genomic Sequencing Classifier (GSC) is highly accurate in…
Read More